Home › Multiple Sclerosis › NCT06136728
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis
Who can join
Ages 25 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Confirmed diagnosis of MS * Expanded Disability Status Scale (EDSS) 6.5 or less * Timed 25-Foot Walk 6-45 seconds (average of 2 trials) * Able to stand unsupported for at least 10 seconds * Montreal Cognitive Assessment 23 or higher * Relapse free for at least 3 months * Not currently taking dalfampridine or not previously taken and discontinued due to adverse reactions * Not currently receiving physical therapy Exclusion Criteria: * Co-existing neurological disorders or orthopedic conditions affecting mobility and physical activity * Unable to follow a 3-step verbal command in English * Hospitalization for any reason in the last 3 months * Uncontrolled hypertension or diabetes * History of seizures * Renal impairment * Women who are breastfeeding, pregnant, or trying to become pregnant * Contraindications to magnetic resonance imaging (MRI; to be excluded from MRI procedures but may participate if all other criteria are met)
About the study
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are:
* Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own? * How do the individual treatments (dalfampridine, physical therapy) alone compare to each other?
Participants with MS-related mobility deficits will:
* Receive 6 weeks of dalfampridine treatment to assess the effects of this treatment. * After stopping the medication for 2 weeks, the investigators will re-evaluate walking, then randomly assign individuals to a 6-week physical therapy program. * Half of the participants will receive physical therapy while resuming dalfampridine treatment. The other half of the participants will receive physical therapy without resuming the medication.
Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.
What is being tested
- Dalfampridine 10 MG [Ampyra] (drug)
- Physical therapy (behavioral)
- Dalfampridine plus physical therapy (other)
Sponsor: MGH Institute of Health Professions · Participants: 48 · Started: Jun 12, 2024
Contact the study team
- Prudence Plummer, PhD · Phone: 617-724-3103
Official record on ClinicalTrials.gov — NCT06136728
Locations in the U.S.
| Massachusetts | MGH Institute of Health Professions, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.